Teleflex Incorporated (NYSE:TFX) Receives Consensus Rating of “Hold” from Analysts

Shares of Teleflex Incorporated (NYSE:TFX) have received an average recommendation of “Hold” from the twelve brokerages that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $141.8750.

TFX has been the subject of several recent analyst reports. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $135.00 price objective on shares of Teleflex in a research report on Wednesday, December 17th. Truist Financial raised their price target on Teleflex from $120.00 to $135.00 and gave the company a “hold” rating in a research note on Thursday, December 18th. Wells Fargo & Company lifted their price target on Teleflex from $114.00 to $139.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. Needham & Company LLC upgraded Teleflex from a “hold” rating to a “buy” rating and set a $138.00 price objective on the stock in a report on Tuesday. Finally, Wall Street Zen lowered Teleflex from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th.

Teleflex Price Performance

TFX stock opened at $105.33 on Thursday. The business’s 50-day moving average is $116.20 and its two-hundred day moving average is $119.73. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.57 and a quick ratio of 1.53. The firm has a market capitalization of $4.65 billion, a P/E ratio of -14.33, a P/E/G ratio of 1.36 and a beta of 0.93. Teleflex has a 1 year low of $100.18 and a 1 year high of $184.58.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, November 6th. The medical technology company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $3.38 by $0.29. The business had revenue of $892.90 million during the quarter, compared to the consensus estimate of $892.79 million. Teleflex had a positive return on equity of 15.64% and a negative net margin of 10.28%.The business’s revenue for the quarter was up 19.4% on a year-over-year basis. During the same period in the previous year, the company posted $3.49 earnings per share. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS. Analysts anticipate that Teleflex will post 13.98 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 15th. Stockholders of record on Friday, November 14th were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 1.3%. The ex-dividend date was Friday, November 14th. Teleflex’s payout ratio is currently -18.50%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Eos Management L.P. purchased a new stake in Teleflex in the fourth quarter valued at $3,763,000. Ruffer LLP acquired a new stake in shares of Teleflex during the fourth quarter worth about $5,154,000. M&T Bank Corp lifted its holdings in shares of Teleflex by 1,102.7% in the 4th quarter. M&T Bank Corp now owns 49,262 shares of the medical technology company’s stock valued at $6,012,000 after purchasing an additional 45,166 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its position in shares of Teleflex by 227.5% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 27,822 shares of the medical technology company’s stock valued at $3,395,000 after purchasing an additional 19,327 shares during the period. Finally, Waterfront Wealth Inc. acquired a new stake in shares of Teleflex in the 4th quarter valued at about $2,050,000. 95.62% of the stock is owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.